Objective: To investigate the clinical efficacy of Shexiang Tongxin dropping pills combined with trimetazidine in treating ischemic heart failure(IHF) and its effects on inflammatory factors. Method: One hundred and twelve IHF cases were randomly divided into control group and research group with 56 cases of each group. The patients in control group were given with trimetazidine

tid and 1 tablet/time. Based on the treatment in control group

the patients in research group were also given with Shexiang Tongxin dropping pills

2 pills/time and tid. The treatment course was 12 weeks in both groups. Left ventricular mass index (LVMI)

mean wall stress (MWS)

B-type natriuretic peptide (NT-Pro BNP)

symptom scores of syndrome of deficiency of heart Qi and blood stasis

level of heart rate variability (HRV)

and clinical efficacy were compared between two groups. The levels of S100 calcium binding protein A8/A9 complex (S100A8/A9)

nuclear transcription factor (NF)-κB

and receptor for advanced glycation end products (RAGE) were detected in both groups. Result: After treatment

MWS

LVMI

NT-Pro BNP

and symptom score of syndrome of deficiency of heart Qi and blood stasis in research group were obviously lower than those in control group (P<0.01). The total effective rate was 94.83% in research group

superior to 79.31% in control group (P<0.05). Normal R-R interval standard deviation (SDNN)

normal R-R interval mean standard deviation (SDANN)

root mean square difference value of adjacent R-R intervals (RMSSD)

adjacent normal R-R interval difference >50 ms beat number accounted for the total number of percentage of stroke (PNN50) were higher than the control group (P<0.01). And the levels of S100A8/A9

NF-κB

and RAGE in serum of research group were significantly lower than those of control group (P<0.01). Conclusion: Shexiang Tongxin dropping pills combined with trimetazidine had significant clinical efficacy in treating IHF

and can inhibit levels of inflammatory factor such as S100A8/A9

NF-κB

and RAGE.